While Collegium Pharmaceutical Inc has underperformed by -2.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, COLL rose by 61.88%, with highs and lows ranging from $47.50 to $23.23, whereas the simple moving average jumped by 44.74% in the last 200 days.
On January 10, 2025, Needham Upgraded Collegium Pharmaceutical Inc (NASDAQ: COLL) to Buy. A report published by H.C. Wainwright on July 30, 2024, Upgraded its rating to ‘Buy’ for COLL. Jefferies also Upgraded COLL shares as ‘Buy’, setting a target price of $44 on the company’s shares in a report dated June 07, 2024. Needham May 10, 2024d its ‘Buy’ rating to ‘Hold’ for COLL, as published in its report on May 10, 2024. Jefferies’s report from January 04, 2024 suggests a price prediction of $37 for COLL shares, giving the stock a ‘Hold’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Collegium Pharmaceutical Inc (COLL)
Further, the quarter-over-quarter increase in sales is 31.42%, showing a positive trend in the upcoming months.
Collegium Pharmaceutical Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 22.96% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.27, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and COLL has an average volume of 432.15K. On a monthly basis, the volatility of the stock is set at 3.76%, whereas on a weekly basis, it is put at 4.84%, with a gain of 14.07% over the past seven days. Furthermore, long-term investors anticipate a median target price of $46.80, showing growth from the present price of $46.38, which can serve as yet another indication of whether COLL is worth investing in or should be passed over.
How Do You Analyze Collegium Pharmaceutical Inc Shares?
Drug Manufacturers – Specialty & Generic giant Collegium Pharmaceutical Inc (COLL) is based in the USA and is one of the largest companies in the market. When comparing Collegium Pharmaceutical Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 28.87, there is a growth in quarterly earnings of 213.22%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.19%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 112.85% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
